lncRNA FENDRR Exhibits Anti-Fibrotic Activity in Pulmonary Fibrosis.
Abnormal activation of lung fibroblasts contributes to the initiation and progression of idiopathic pulmonary fibrosis (IPF). The objective of the current study was to investigate the role of FENDRR in the activation of lung fibroblasts. Dysregulated lncRNAs in IPF lungs were identified by next generation sequencing analysis from the two online datasets. FENDRR expression in lung tissues from patients with IPF and mice with bleomycin-induced pulmonary fibrosis was determined by quantitative real-time polymerase chain reaction. Iron-responsive element-binding protein 1 (IRP1), a protein partner of FENDDR, was identified by RNA pulldown-coupled mass spectrometry analysis and confirmed by RNA immunoprecipitation. The interaction region between FENDRR and IRP1 was determined by cross-linking immunoprecipitation. The in vivo role of FENDRR in pulmonary fibrosis was studied using adenovirus-mediated gene transfer in mice. The expression of FENDRR was down-regulated in fibrotic human and mouse lungs as well as primary lung fibroblasts isolated from bleomycin-treated mice. TGFβ1-SMAD3 signaling inhibited FENDRR expression in lung fibroblasts. FENDRR was preferentially localized in the cytoplasm of adult lung fibroblasts and bound IRP1, suggesting its role in iron metabolism. FENDRR reduced pulmonary fibrosis by inhibiting fibroblast activation by reducing iron level and acting as a competing endogenous RNA of the profibrotic miR-214. Adenovirus-mediated FENDRR gene transfer in the mouse lung attenuated bleomycin-induced lung fibrosis and improved lung function. Our data suggest that FENDRR is an anti-fibrotic lncRNA and a potential therapeutic target for pulmonary fibrosis.